posted on 2023-02-09, 09:05authored byIvana Mejdrová, Jan Dušek, Kryštof Škach, Alžbeta Stefela, Josef Skoda, Karel Chalupský, Klára Dohnalová, Ivona Pavkova, Thales Kronenberger, Azam Rashidian, Lucie Smutná, Vojtěch Duchoslav, Tomas Smutny, Petr Pávek, Radim Nencka
The nuclear constitutive androstane receptor (CAR, NR1I3)
plays
significant roles in many hepatic functions, such as fatty acid oxidation,
biotransformation, liver regeneration, as well as clearance of steroid
hormones, cholesterol, and bilirubin. CAR has been proposed as a hypothetical
target receptor for metabolic or liver disease therapy. Currently
known prototype high-affinity human CAR agonists such as CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime)
have limited selectivity, activating the pregnane X receptor (PXR)
receptor, a related receptor of the NR1I subfamily. We have discovered
several derivatives of 3-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine that directly activate human CAR in nanomolar
concentrations. While compound 39 regulates CAR target
genes in humanized CAR mice as well as human hepatocytes, it does
not activate other nuclear receptors and is nontoxic in cellular and
genotoxic assays as well as in rodent toxicity studies. Our findings
concerning potent human CAR agonists with in vivo activity reinforce
the role of CAR as a possible therapeutic target.